A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer.
Delaney JR, Patel C, McCabe KE, Lu D, Davis MA, Tancioni I, von Schalscha T, Bartakova A, Haft C, Schlaepfer DD, Stupack DG.
Delaney JR, et al. Among authors: davis ma.
Oncotarget. 2015 Oct 13;6(31):31104-18. doi: 10.18632/oncotarget.5093.
Oncotarget. 2015.
PMID: 26418751
Free PMC article.